Clinical Evaluation

Orbach, Egmont J.
April 1957
Angiology;Apr1957, Vol. 8 Issue 2, p204
Academic Journal
Focuses on the rules in the clinical evaluation of drugs from pharmaceutical laboratories, invention of new devices for diagnostic and therapeutics purposes, design of operative procedures in the field of angiology. Requirement of comparable series in the evaluation of a drug or an operative procedure for the treatment of vascular ulcerations; Proof to the effect of a certain drug or therapeutic measure; Elimination of subjective symptoms in the survey.


Related Articles

  • Reducing Operative Mortality in Aortic Aneurysm Repair. Walling, Anne D. // American Family Physician;6/15/2005, Vol. 71 Issue 12, p2368 

    Presents the results of a randomized controlled trial comparing mortality patients who underwent endovascular aneurysm repair (EVAR) with open repair of abdominal aortic aneurysm. Length of hospital stay among patients in the EVAR group; Mean operating time of EVAR; Percentage of reduction in...

  • Reviewer�s comment. Weidner, Andreas // European Spine Journal;Dec2000, Vol. 9 Issue 6, p545 

    The article states that the treatment of cervical myelopathy is still a matter of debate in the literature. This randomized and prospective study gives valuable information to the reader and should be very helpful in the process of deciding whether surgery or conservative treatment is indicated....

  • Sulfasalazine and Mesalazine for the Maintenance Therapy of Crohn's Disease: A Meta-analysis. Steinhart, A. Hilary; Hemphill, Doug; Greenberg, Gordon R. // American Journal of Gastroenterology;Dec1994, Vol. 89 Issue 12, p2116 

    Objective: The aim of this meta-analysis was to deter-mine whether therapy with sulfasalazine or mesalazine is effective in the maintenance of clinical remission in patients with Crohn's disease. Methods: Computerized searches of bibliographic databases were carried out to identify studies...

  • Design Issues in Randomized Clinical Trials of Maintenance Therapies. Freidlin, Boris; Little, Richard F.; Korn, Edward L. // JNCI: Journal of the National Cancer Institute;Nov2015, Vol. 107 Issue 11, p1 

    A potential therapeutic strategy for patients who respond (or have stable disease) on a fixed-duration induction therapy is to receive maintenance therapy, typically given for a prolonged period of time. To enable patients and clinicians to make informed treatment decisions, the designs of phase...

  • Fracture risk and the use of a diuretic (indapamide sr) ± perindopril: a substudy of the Hypertension in the Very Elderly Trial (HYVET). Bulpitt, Christopher J.; Peters, Ruth; Staessen, Jan A.; Thijs, Lutgarde; De Vernejoul, Marie-Christine; Fletcher, Astrid E.; Beckett, Nigel S. // Trials;2006, Vol. 7, p33 

    Background: The Hypertension in the Very Elderly Trial (HYVET) is a placebo controlled double blind trial of treating hypertension with indapamide Slow Release (SR) ± perindopril in subjects over the age of 80 years. The primary endpoints are stroke (fatal and non fatal). In view of the fact...

  • Vascular Medicine: The Role of the Vascular Surgeon. Pearce, William H. // Vascular Surgery;Jan/Feb1998, Vol. 32 Issue 1, p1 

    The article comments on the role of the role of vascular surgeons in the field of vascular medicine. The author points that vascular medicine is based on the pursuit of academic excellence with the understanding of all vascular diseases in broadest terms. Vascular surgeons play a vital part in...

  • EVEREST Trial 2-Year Results Show Stability of Percutaneous MV Repair Between Years 1 and 2.  // MD Conference Express;May2011, p17 

    The article presents results from the Endovascular Valve Edge-to-Edge Repair trial (EVEREST) indicating the safety and durability of percutaneous mitral valve (MV) repair with measurable clinical benefits. The trial reveals the significance of MV repair as a therapy for patients having mitral...

  • News Update.  // Applied Clinical Trials;Jun2000, Vol. 9 Issue 6, p12 

    Reports on developments relating to clinical trial management as of June 2000. Inclusion of the United States Food and Drug Administration's approval of Novartis Pharmaceuticals Corp.'s Exelon, capsules for treating Alzheimer's disease; Phase 3 study of Sensus Drug Development Corp.'s use of...

  • Research Provides Golden Opportunity for Physicians. Nylen, Ruth Ann // Physician Executive;Jan/Feb2002, Vol. 28 Issue 1, p32 

    Presents an overview on pharmaceutical clinical research trials. Definition of clinical research; Drug development process; Phases of clinical trials; Role of the physician in the trials; Roles and responsibilities of the sponsor, investigator and clinical research coordinator in the trials;...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics